Pediatrix Medical Group (MD) closed the last trading session at $13.56, gaining 10.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $17.14 indicates a 26.4% upside potential.The mean estimate comprises seven short-term price targets with a standard deviation of $2.61. While the lowest estimate of $14 indicates a 3.2% increase from the current price level, the most optimistic anal ...

Group 1 - Shift4 Payments (FOUR) shares have increased by 17.2% over the past four weeks, closing at $90.26, with a mean price target of $114.83 indicating a potential upside of 27.2% [1] - The average of 23 short-term price targets ranges from a low of $80 to a high of $150, with a standard deviation of $15.53, suggesting variability in analyst estimates [2] - Analysts show strong agreement in revising earnings estimates higher, with the Zacks Consensus Estimate for the current year increasing by 20.2% over the past month [11][12] Group 2 - FOUR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The correlation between earnings estimate revisions and near-term stock price movements supports the expectation of an upside in FOUR [11] - While price targets are often viewed skeptically, the direction implied by the consensus price target may serve as a useful guide for potential price movement [10][13]

Core Viewpoint - Karyopharm Therapeutics (KPTI) shows significant upside potential with a mean price target of $33.07, indicating a 521.6% increase from its current price of $5.32 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from $8 to $67.47, with a standard deviation of $23.37, suggesting a high variability in analyst predictions [2] - The lowest estimate indicates a potential increase of 50.4%, while the highest suggests an upside of 1168.2% [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Optimism - Analysts exhibit strong agreement in revising KPTI's earnings estimates higher, which correlates with potential stock price increases [4][11] - Over the past 30 days, one estimate has increased, leading to a 4.9% rise in the Zacks Consensus Estimate for the current year [12] - KPTI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Seres Therapeutics (MCRB) shows significant upside potential with a mean price target of $60.25, indicating a 713.1% increase from its current price of $7.41 [1] Price Targets and Analyst Consensus - The average price target for MCRB ranges from a low of $6 to a high of $200, with a standard deviation of $93.35, indicating high variability among analysts [2] - The lowest estimate suggests a 19% decline from the current price, while the highest estimate indicates a potential upside of 2599.1% [2] - A tight clustering of price targets, represented by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising MCRB's earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 80.3%, with three estimates moving higher and no negative revisions [12] - MCRB holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - Arcturus Therapeutics (ARCT) shows significant upside potential based on Wall Street analysts' short-term price targets, with a mean target of $65.43 indicating a 503.6% increase from the current price of $10.84 [1] Price Targets and Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $34.14, indicating variability among analysts. The lowest estimate of $44 suggests a 305.9% increase, while the highest estimate predicts a surge of 1191.5% to $140 [2] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about ARCT's earnings prospects, as indicated by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 28.3% over the last 30 days, with four estimates moving higher and no negative revisions [11][12] - ARCT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside in the near term [13] Caution on Price Targets - While the consensus price target is a commonly referenced metric, relying solely on it for investment decisions may not be prudent due to historical inaccuracies in analysts' price targets [3][7][10] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

Core Viewpoint - Dream Finders Homes Inc. (DFH) has shown a significant price increase of 11.1% over the past four weeks, with a mean price target of $29.50 indicating a potential upside of 26.8% from the current price of $23.26 [1] Price Targets and Analyst Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $4.44, where the lowest estimate is $26 (an 11.8% increase) and the highest is $34.50 (a 48.3% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about DFH's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a 2.9% increase in the Zacks Consensus Estimate for the current year [11][12] - DFH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be wise, as analysts' price targets can often be overly optimistic due to business incentives [3][8][10]

Shares of Enanta Pharmaceuticals (ENTA) have gained 5.1% over the past four weeks to close the last trading session at $5.18, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15 indicates a potential upside of 189.6%.The mean estimate comprises six short-term price targets with a standard deviation of $7.27. While the lowest estimate of $5 indicates a 3.5% decline from the curre ...

Core Viewpoint - Janus International Group, Inc. (JBI) has shown a significant price increase of 35.6% over the past four weeks, with a mean price target of $10.80 indicating a potential upside of 27.1% from the current price of $8.50 [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $3.11, indicating variability among analysts; the lowest estimate is $7 (17.7% decline), while the highest is $14 (64.7% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement direction, although it does not guarantee the stock will reach the average target [9] Earnings Estimates and Market Sentiment - Analysts are optimistic about JBI's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 35.4% over the past month, with no negative revisions reported [12] - JBI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for upside in the near term [13]

Group 1 - Edgewise Therapeutics, Inc. (EWTX) shares have increased by 14.4% over the past four weeks, closing at $14.89, with a mean price target of $40.90 indicating a potential upside of 174.7% [1] - The average of 10 short-term price targets ranges from a low of $14 to a high of $52, with a standard deviation of $14.28, suggesting variability in analyst estimates [2] - Analysts show strong agreement on EWTX's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for EWTX's current year earnings has increased by 6.8% over the past month, with four estimates rising and one falling [12] - EWTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for near-term upside [13] - While consensus price targets may not be reliable for predicting exact stock gains, they can provide a directional guide for price movement [13]

Core Viewpoint - BridgeBio Pharma (BBIO) shows potential for significant upside, with a mean price target of $58.47 indicating a 63.9% increase from its current price of $35.68 [1] Price Targets and Estimates - The mean estimate consists of 17 short-term price targets with a standard deviation of $12.24, suggesting variability in analyst predictions [2] - The lowest estimate is $37, indicating a 3.7% increase, while the highest estimate is $95, suggesting a potential surge of 166.3% [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism regarding BBIO's earnings, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 16.6% over the past month, with eight estimates increasing and one decreasing [12] - BBIO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]